Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease

被引:6
|
作者
Fan, Hong [1 ,2 ,3 ,4 ]
Li, Lili [1 ,2 ,5 ]
Liu, Zhenqiu [4 ,6 ,7 ,8 ]
Zhang, Pengyan [1 ,2 ,3 ,4 ]
Wu, Sheng [1 ,2 ,3 ]
Han, Xinyu [1 ,2 ,3 ]
Chen, Xingdong [3 ,4 ,6 ,7 ,8 ]
Suo, Chen [1 ,2 ,3 ,4 ]
Cao, Liou [5 ]
Zhang, Tiejun [1 ,2 ,3 ,4 ]
机构
[1] Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai 200032, Peoples R China
[2] Fudan Univ, Key Lab Publ Hlth Safety, Minist Educ, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Inst Infect Dis & Biosecur, Sch Publ Hlth, Shanghai, Peoples R China
[4] Fudan Univ, Taizhou Inst Hlth Sci, Taizhou, Peoples R China
[5] Affiliated Shanghai Univ Med & Hlth Sci, Jiading Dist Cent Hosp, Shanghai 200032, Peoples R China
[6] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200438, Peoples R China
[7] Fudan Univ, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci, Shanghai 200438, Peoples R China
[8] Fudan Univ, Human Phenome Inst, 825 Zhangheng Rd, Shanghai, Peoples R China
关键词
Fatty liver disease; MAFLD; Fibrosis; Low-normal thyroid function; Subclinical hypothyroidism; NONALCOHOLIC STEATOHEPATITIS; SUBCLINICAL HYPOTHYROIDISM; EUTHYROID SUBJECTS; NATIONAL-HEALTH; HORMONES; NAFLD;
D O I
10.1186/s12876-022-02612-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims Observational studies showed that low thyroid function may perturb liver function. We aimed to evaluate the association of low thyroid function with both metabolic dysfunction-associated fatty liver disease (MAFLD) and advanced hepatic fibrosis.Methods Participants who underwent abdominal ultrasonography and thyroid function test in a Chinese hospital from 2015 to 2021were enrolled. Fibrosis-4 index (FIB-4) > 2.67 and/or non-alcoholic fatty liver disease fibrosis score (NFS) > 0.676 were used to define advanced fibrosis. Descriptive analyses were performed to characterize the epidemiology of MAFLD according to levels of thyroid-stimulating hormone (TSH). The logistic regression model was applied to estimate the association of low thyroid function with MAFLD and advanced fibrosis.Results A total of 19,946 participants (52.78% males, mean age: 47.31 years, 27.55% MAFLD) were included, among which 14,789 were strict-normal thyroid function, 4,328 were low-normal thyroid function, 829 were subclinical hypothyroidism. TSH levels were significantly higher in MAFLD patients with a FIB-4 > 2.67 and /or NFS > 0.676 than their counterparts. The logistic regression model adjusted for age and sex showed that low-normal thyroid function increased the risk of MAFLD (odds ratio [OR] = 1.09; 95% confidence interval [CI] 1.01-1.18). Multivariable regression model adjusted for age, sex, body mass index, type 2 diabetes, and hypertension showed low-normal thyroid function increased the risk of advanced fibrosis in patients with MAFLD (FIB-4 > 2.67: OR = 1.41, 95% CI 1.02-1.93; NFS > 0.676: OR = 1.72, 95% CI 1.08-2.72).Conclusion Elevated TSH concentrations are associated with advanced hepatic fibrosis, even in the euthyroid state.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Metabolic dysfunction-associated fatty liver disease in people living with HIV
    Michel, Maurice
    Labenz, Christian
    Armandi, Angelo
    Kaps, Leonard
    Kremer, Wolfgang Maximilian
    Galle, Peter R.
    Grimm, Daniel
    Sprinzl, Martin
    Schattenberg, Joern M.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [42] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    GUT, 2024, 73 (03) : 533 - 540
  • [43] Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
    Zhou, Xiao-Dong
    Cai, Jingjing
    Targher, Giovanni
    Byrne, Christopher D.
    Shapiro, Michael D.
    Sung, Ki-Chul
    Somers, Virend K.
    Chahal, C. Anwar A.
    George, Jacob
    Chen, Li-Li
    Zhou, Yong
    Zheng, Ming-Hua
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [44] Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population
    Lee, Guan Huei
    Phyo, Wah Wah
    Loo, Wai Mun
    Kwok, Raymond
    Ahmed, Taufique
    Shabbir, Asim
    So, Jimmy
    Koh, Calvin Jianyi
    Hartono, Juanda Leo
    Muthiah, Mark
    Lim, Kieron
    Tan, Poh Seng
    Lee, Yin Mei
    Lim, Seng Gee
    Dan, Yock Young
    WORLD JOURNAL OF HEPATOLOGY, 2020, 12 (12) : 1228 - 1238
  • [45] Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
    Lim, Tae Seop
    Chun, Ho Soo
    Kim, Soon Sun
    Kim, Ja Kyung
    Lee, Minjong
    Cho, Hyo Jung
    Kim, Seung Up
    Cheong, Jae Youn
    GUT AND LIVER, 2023, 17 (04) : 610 - 619
  • [46] Far-infrared radiation alleviates steatohepatitis and fibrosis in metabolic dysfunction-associated fatty liver disease
    Xu, Tianyi
    Fu, Haijing
    Zhao, Wumei
    Shan, Shijun
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [47] Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions
    Beygi, Mohammad
    Ahi, Salma
    Zolghadri, Samaneh
    Stanek, Agata
    NUTRIENTS, 2024, 16 (14)
  • [48] The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease
    Goya, Takeshi
    Imoto, Koji
    Tashiro, Shigeki
    Aoyagi, Tomomi
    Takahashi, Motoi
    Kurokawa, Miho
    Suzuki, Hideo
    Tanaka, Masatake
    Kato, Masaki
    Kohjima, Motoyuki
    Ogawa, Yoshihiro
    GASTROENTEROLOGY INSIGHTS, 2022, 13 (01) : 20 - 26
  • [49] Acute-on-chronic liver failure in metabolic dysfunction-associated fatty liver disease patients: a disease multiplier
    Choudhury, Ashok
    Rajaram, Ruveena
    Sarin, Shiv Kumar
    HEPATOLOGY INTERNATIONAL, 2024, 18 (SUPPL 2) : 941 - 958
  • [50] Association of metabolic dysfunction-associated fatty liver disease with kidney disease
    Wang, Ting-Yao
    Wang, Rui-Fang
    Bu, Zhi-Ying
    Targher, Giovanni
    Byrne, Christopher D.
    Sun, Dan-Qin
    Zheng, Ming-Hua
    NATURE REVIEWS NEPHROLOGY, 2022, 18 (04) : 259 - 268